D-0256-2025 Class II Ongoing

Recalled by Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

FDA drug recall D-0256-2025 was initiated by Zydus Pharmaceuticals (USA) Inc on Feb 13, 2025 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications The recall status is ongoing. Affected quantity: 1,893 vials.

Recall details

Product Type
Drugs
Report Date
Mar 12, 2025
Initiation Date
Feb 13, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,893 vials

Product description

Nelarabine Injection, 250mg/50mL, (5mg/mL), packaged in: a) 50 mL Single-Dose Vial, NDC 70710-1839-1; b) 6 x 50 mL Single-Dose Vial, NDC 70710-1839-8, Rx only, Manufactured by Zydus Lifesciences Ltd, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc, Pennington, NJ

Reason for recall

Failed Impurities/Degradation Specifications

Distribution pattern

USA Nationwide

Code information

Lot: a) P300197, Exp. Aug-2025; P400113, Exp. May-26; b) P300169, Exp. Jun-2025; P400115, Exp. May-2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0256-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0256-2025. Report a data issue: hello@regdatalab.com.